Prior authorization required for targeted phototherapy in topical‑resistant mild psoriasis

Targeted phototherapy may be considered for patients with mild psoriasis that is resistant to topical medications; obtain prior authorization that documents failure of topical therapies and that targeted phototherapy is being used as an alternative to whole‑body UVB.

• Document prior topical therapy attempts and inadequate response.
• State that targeted phototherapy is chosen to avoid whole‑body UVB exposure.

Prior authorization recommended for PUVA in moderate‑to‑severe psoriasis

PUVA is typically reserved for more severe or generalized psoriasis and prior authorization should be obtained when used for patients with >10% body surface area involvement or refractory disease.

• Indicate % body surface area or clinical justification for moderate‑to‑severe designation.
• Provide prior treatment history showing refractory disease.

Contact BCBSKS for prior authorization guidance

For coverage questions or if prior authorization requirements are unclear, contact Blue Cross and Blue Shield of Kansas customer service or your professional/institutional relations representative; the policy extract does not provide a specific prior authorization form.

• No explicit prior authorization form is provided in this policy text—use BCBSKS contact channels for guidance.

Prior authorization may be required for listed phototherapy procedures/devices

Certain ultraviolet therapies and devices are listed with procedure and HCPCS codes; prior authorization may be required per the member's contract and medical necessity criteria.

• Codes include 96900, 96912, 96920‑96922, E0691‑E0694, and J8999.
• Confirm prior authorization requirements with member contract and BCBSKS.

Codes listed only if Policy criteria and member benefits are met

The procedure and HCPCS codes listed in the policy are informational; coverage is contingent on meeting the Policy section requirements and the member's contract—codes are medically necessary only if the procedure is performed according to the Policy.

• Do not assume inclusion of a code guarantees coverage or reimbursement.
• Ensure treatments meet Policy criteria to support medical necessity for billed codes.

Step therapy: require topical therapy trial before targeted phototherapy

Topical medications (e.g., topical steroids, vitamin D analogues, tazarotene, coal tar) are first‑line for mild localized psoriasis; targeted phototherapy is considered only after lesions are resistant to topical therapy.

• Document trials of appropriate topical agents and inadequate response before initiating targeted phototherapy.

Step therapy: document escalation before PUVA

Evidence indicates PUVA can be more effective than NB‑UVB and topical steroids for moderate‑to‑severe psoriasis; therefore, step therapy may require trial and failure of less intensive therapies before authorization of PUVA.

• Provide documentation of prior NB‑UVB or topical therapy trials and outcomes when requesting PUVA.

Comparator: NB‑UVB is standard of care

The standard comparator for targeted phototherapy in the evidence base is narrowband UVB (NB‑UVB) light box therapy; topical medications and NB‑UVB are the current comparators to describe prior treatment and sequencing.

• When describing prior therapy, note whether NB‑UVB was tried or considered as the standard comparator.

Therapy sequencing: reserve PUVA for after conservative therapy fails

PUVA is considered an alternative when conservative therapy fails; NB‑UVB is the most described standard and should be considered in sequencing before more toxic options.

• Explain why PUVA is chosen over NB‑UVB for individual patients when submitting authorization.

Follow current BCBSKS policy and member contract for sequencing

Follow the current policy criteria and payer guidance for stepwise treatment requirements; policy history has revised medically necessary statements and limits over time, so rely on the active policy and BCBSKS direction.

• Verify the most recent policy version and applicable member contract before submitting requests.

Documentation: baseline and long‑term follow‑up required

Document baseline disease status, prior topical treatments and responses, and follow‑up assessments (symptoms, disease status, quality of life, and treatment‑related morbidity); typical follow‑up for mild localized psoriasis occurs months to years after starting treatment.

• Record baseline lesion counts/locations and previous topical regimens and durations.
• Include follow‑up notes addressing response and adverse events over months to years.

Document clinical details consistent with study selection criteria

Align documentation with the populations and outcomes used in study selection: record disease extent (e.g., generalized >10% BSA where relevant), interventions tried, comparators, outcomes, and prespecified clinical endpoints.

• For generalized psoriasis, document % BSA (threshold >10% where applicable).
• Support clinical indication with evidence‑aligned data (PASI scores, repigmentation, etc.) when available.

Document number of treatment sessions and follow‑up (retrospective study benchmarks)

Retrospective studies report number of treatment sessions and follow‑up (examples: 10 sessions; 16–20 sessions; mean 20 sessions); include the number of sessions delivered and follow‑up duration in clinical records.

• Record total number of treatment sessions and timing when submitting outcomes or appeals.
• If using retrospective study benchmarks, note session counts (e.g., 16–20 treatments) and observed outcomes.

Medical necessity documentation: retain records showing adherence to Policy

To support medical necessity, document that the procedure was performed according to the Policy section and retain records of treatment modality, number of sessions, indication, and response.

• Include explicit statement that the service met Policy criteria when submitting claims or appeals.
• Keep treatment logs, session counts, and clinician assessments in the record.

Billing rule: codes are medically necessary only with Policy‑compliant performance

The listed codes are medically necessary only if the procedure is performed according to the Policy section; ensure that coding matches documented adherence to policy criteria to avoid coverage denials.

• Cross‑check billed CPT/HCPCS codes with documented indication and Policy adherence.
• Be aware that inclusion of codes in the policy does not itself guarantee coverage.

Denial risk: do not use phototherapy if topical therapy adequately controls disease

Phototherapy is not recommended for patients with mild localized psoriasis whose disease can be controlled with topical medications; initiating phototherapy in such cases may lead to coverage denial.

• If topical therapy controls disease, avoid phototherapy or document clear clinical rationale for escalation.

Contact BCBSKS for coverage inquiries and denial handling

For questions about coverage or potential denials, contact Blue Cross and Blue Shield of Kansas customer service or your professional/institutional relations representative for assistance.

• Use BCBSKS contact channels for pre‑authorization clarifications or appeals.

Policy monitoring: no scheduled update; BCBSKS will monitor literature

Blue Cross and Blue Shield of Kansas will continue to monitor the literature; there is no scheduled review or update—contact BCBSKS for updates if needed.

• Providers should rely on current policy language and BCBSKS contacts for the latest guidance.

Coding inclusion does not guarantee coverage or reimbursement

Inclusion or exclusion of procedure, diagnosis, or device codes in the policy is informational and does not guarantee member coverage or provider reimbursement; coverage decisions remain subject to the policy's medical necessity criteria and the member's contract.

• Verify member benefits and document Policy compliance to support coverage.